Humacyte develops products for vascular diseases and replacement of anatomical conduits.
About Humacyte Stock
Humacyte, Inc. develops products for vascular disease and replacement of anatomical conduits. It offers human tissue-based products for regenerative medicine and vascular surgery applications; off-the-shelf extracellular matrix tissue products, which are formed in vitro from banked vascular smooth muscle cells and then decellularized to eliminate the risk of rejection; and vascular grafts. The company was incorporated in 2004 and is headquartered in Morrisville, North Carolina.
Co-Founder and VP
Juliana L. Blum
Theodore D. Lithgow
Founder & CTO
Laura E. Niklason
Wall Streets Journal - Jun, 11 2018